OptimizeRx (NASDAQ:OPRX) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

by · The Markets Daily

OptimizeRx (NASDAQ:OPRX – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05, FiscalAI reports. The firm had revenue of $20.50 million during the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded up $0.12 during trading hours on Wednesday, reaching $7.04. 325,517 shares of the stock traded hands, compared to its average volume of 422,567. The company has a 50 day moving average price of $5.93 and a 200 day moving average price of $6.77. The firm has a market capitalization of $132.11 million, a price-to-earnings ratio of 20.11 and a beta of 1.08. OptimizeRx has a one year low of $4.54 and a one year high of $22.25. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its position in OptimizeRx by 29.9% in the second quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock worth $487,000 after acquiring an additional 8,297 shares during the period. American Century Companies Inc. grew its position in shares of OptimizeRx by 52.5% during the 2nd quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock valued at $325,000 after acquiring an additional 8,286 shares during the period. Russell Investments Group Ltd. increased its stake in shares of OptimizeRx by 141.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock worth $1,493,000 after purchasing an additional 64,790 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx in the 2nd quarter worth $44,000. Finally, WINTON GROUP Ltd bought a new position in OptimizeRx in the 2nd quarter worth $286,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Stephens lowered their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 13th. B. Riley Financial cut their target price on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings lowered OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, May 14th. Finally, Lake Street Capital decreased their price target on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.43.

Get Our Latest Stock Report on OptimizeRx

About OptimizeRx

(Get Free Report)

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.

Featured Stories